PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24451154-9 2014 RESULTS: Here we describe the acquisition of a hotspot PIK3CA mutation in cells selected for resistance to the HER2 tyrosine kinase inhibitor lapatinib. Lapatinib 142-151 erb-b2 receptor tyrosine kinase 2 Mus musculus 111-115 24451154-12 2014 In mice bearing HER2-amplified wild-type PIK3CA xenografts, dual HER2 targeting with trastuzumab and lapatinib resulted in tumor regression. Lapatinib 101-110 erb-b2 receptor tyrosine kinase 2 Mus musculus 16-20 24451154-12 2014 In mice bearing HER2-amplified wild-type PIK3CA xenografts, dual HER2 targeting with trastuzumab and lapatinib resulted in tumor regression. Lapatinib 101-110 erb-b2 receptor tyrosine kinase 2 Mus musculus 65-69 23843024-1 2013 The dual erbB1/2 tyrosine kinase inhibitor lapatinib as well as the anthracycline doxorubicin are both used in the therapy of HER2-positive breast cancer. Lapatinib 43-52 erb-b2 receptor tyrosine kinase 2 Mus musculus 126-130 24384723-10 2014 In the mouse model of HER2-driven breast cancer, ErbB2 inhibition by Lapatinib strongly suppresses tumor progression, and this is associated with inactivation of the HSF1 pathway. Lapatinib 69-78 erb-b2 receptor tyrosine kinase 2 Mus musculus 22-26 24384723-10 2014 In the mouse model of HER2-driven breast cancer, ErbB2 inhibition by Lapatinib strongly suppresses tumor progression, and this is associated with inactivation of the HSF1 pathway. Lapatinib 69-78 erb-b2 receptor tyrosine kinase 2 Mus musculus 49-54 23843024-2 2013 Using MMTV-neu mice as an animal model for HER2-positive breast cancer, we observed enhanced tumor infiltration by IFN-gamma-secreting T cells after treatment with doxorubicin and/or lapatinib. Lapatinib 183-192 erb-b2 receptor tyrosine kinase 2 Mus musculus 43-47 23569315-1 2013 PURPOSE: We previously reported the eradication of human epidermal growth factor receptor 2 (HER2)- amplified human xenografts in mice by inhibition of the HER2 pathway with lapatinib and trastuzumab to block all homo- and heterodimer signaling as well as by blockade of estrogen receptor (ER) when expressed. Lapatinib 174-183 erb-b2 receptor tyrosine kinase 2 Mus musculus 156-160 23940356-9 2013 Finally, HER2(+)/PIK3CA tumors were resistant to trastuzumab alone and in combination with lapatinib or pertuzumab. Lapatinib 91-100 erb-b2 receptor tyrosine kinase 2 Mus musculus 9-13 22872574-9 2012 This regimen even exhibited activity in lapatinib-resistant HER2(+) tumors. Lapatinib 40-49 erb-b2 receptor tyrosine kinase 2 Mus musculus 60-64 23543055-4 2013 ERBB3 signaling was dependent on ERBB2; targeting ERBB2 with lapatinib in combination with the RAF inhibitor PLX4720 reduced tumor burden and extended latency of tumor regrowth in vivo versus PLX4720 alone. Lapatinib 61-70 erb-b2 receptor tyrosine kinase 2 Mus musculus 33-38 23543055-4 2013 ERBB3 signaling was dependent on ERBB2; targeting ERBB2 with lapatinib in combination with the RAF inhibitor PLX4720 reduced tumor burden and extended latency of tumor regrowth in vivo versus PLX4720 alone. Lapatinib 61-70 erb-b2 receptor tyrosine kinase 2 Mus musculus 50-55 23224399-1 2013 PURPOSE: Dual blockade of HER2 with trastuzumab and lapatinib or with pertuzumab is a superior treatment approach compared with single-agent HER2 inhibitors. Lapatinib 52-61 erb-b2 receptor tyrosine kinase 2 Mus musculus 26-30 23224399-9 2013 Mice bearing HER2(+) xenografts treated with lapatinib, trastuzumab, and U3-1287 exhibited fewer recurrences and better survival than mice treated with lapatinib and trastuzumab. Lapatinib 45-54 erb-b2 receptor tyrosine kinase 2 Mus musculus 13-17 21685235-1 2011 Dual epidermal growth factor receptor (EGFR) and HER2 targeting with the tyrosine kinase inhibitor lapatinib is approved for treating advanced HER2-positive breast cancer and can prevent estrogen receptor (ER)-negative mammary tumors in HER2 transgenic mouse models. Lapatinib 99-108 erb-b2 receptor tyrosine kinase 2 Mus musculus 49-53 22011930-0 2012 Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Lapatinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 26-30 22011930-1 2012 PURPOSE: Lapatinib, a small molecule EGFR/HER2 inhibitor, partially inhibits the outgrowth of HER2+ brain metastases in preclinical models and in a subset of CNS lesions in clinical trials of HER2+ breast cancer. Lapatinib 9-18 erb-b2 receptor tyrosine kinase 2 Mus musculus 42-46 22011930-1 2012 PURPOSE: Lapatinib, a small molecule EGFR/HER2 inhibitor, partially inhibits the outgrowth of HER2+ brain metastases in preclinical models and in a subset of CNS lesions in clinical trials of HER2+ breast cancer. Lapatinib 9-18 erb-b2 receptor tyrosine kinase 2 Mus musculus 94-98 22011930-1 2012 PURPOSE: Lapatinib, a small molecule EGFR/HER2 inhibitor, partially inhibits the outgrowth of HER2+ brain metastases in preclinical models and in a subset of CNS lesions in clinical trials of HER2+ breast cancer. Lapatinib 9-18 erb-b2 receptor tyrosine kinase 2 Mus musculus 94-98 22325452-2 2012 HER2-based vaccines induce polyclonal antibody responses against HER2 that demonstrate enhanced anti-tumor activity when combined with lapatinib in murine models. Lapatinib 135-144 erb-b2 receptor tyrosine kinase 2 Mus musculus 0-4 21499296-8 2011 Finally, the combination of lapatinib and the Src inhibitor AZD0530 was more effective than lapatinib alone at inhibiting pAkt and growth of established HER2-positive BT-474 xenografts in athymic mice. Lapatinib 28-37 erb-b2 receptor tyrosine kinase 2 Mus musculus 153-157 21816844-5 2011 Clinical trials include a recent placebo-controlled phase IIb presurgical trial of the dual EGFR HER2 inhibitor lapatinib that suppressed growth of breast premalignancy [including atypical ductal hyperplasia (ADH) and DCIS] and invasive cancer in patients with early-stage, HER2-overexpressing or -amplified breast cancer. Lapatinib 112-121 erb-b2 receptor tyrosine kinase 2 Mus musculus 97-101 21816844-6 2011 These results suggest that lapatinib can clinically suppress the progression of ADH and DCIS to invasive breast cancer, an effect previously observed in a mouse model of HER2-overexpressing, ER-negative mammary cancer. Lapatinib 27-36 erb-b2 receptor tyrosine kinase 2 Mus musculus 170-174 21685235-1 2011 Dual epidermal growth factor receptor (EGFR) and HER2 targeting with the tyrosine kinase inhibitor lapatinib is approved for treating advanced HER2-positive breast cancer and can prevent estrogen receptor (ER)-negative mammary tumors in HER2 transgenic mouse models. Lapatinib 99-108 erb-b2 receptor tyrosine kinase 2 Mus musculus 143-147 22190871-6 2011 MPPS1 cells maintain high ErbB2 overexpression when propagated in DFCI-1 or related media, and their growth is ErbB2-dependent, as demonstrated by concentration-dependent inhibition of proliferation with the ErbB kinase inhibitor Lapatinib. Lapatinib 230-239 erb-b2 receptor tyrosine kinase 2 Mus musculus 111-116 21482676-2 2011 In a mouse model of mammary carcinoma driven by the polyomavirus middle T (PyVmT) oncogene, the ErbB2 tyrosine kinase inhibitor lapatinib reduced the activation of ErbB3 and Akt as well as tumor cell growth. Lapatinib 128-137 erb-b2 receptor tyrosine kinase 2 Mus musculus 96-101 21482676-3 2011 In this phosphatidylinositol-3 kinase (PI3K)-dependent tumor model, ErbB2 is part of a complex containing PyVmT, p85 (PI3K), and ErbB3, that is disrupted by treatment with lapatinib. Lapatinib 172-181 erb-b2 receptor tyrosine kinase 2 Mus musculus 68-73 22190871-9 2011 Immunofluorescence staining of control vs. Lapatinib-treated acini for markers of epithelial polarity revealed that inhibition of ErbB2 signaling led to rapid resumption of normal mammary epithelium-like cell polarity. Lapatinib 43-52 erb-b2 receptor tyrosine kinase 2 Mus musculus 130-135 18664652-3 2008 We examined the efficacy of lapatinib, an inhibitor of the epidermal growth factor receptor (EGFR) and HER2 kinases, for preventing the outgrowth of breast cancer cells in the brain in a mouse xenograft model of brain metastasis. Lapatinib 28-37 erb-b2 receptor tyrosine kinase 2 Mus musculus 103-107 19536776-0 2009 The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38. Lapatinib 46-55 erb-b2 receptor tyrosine kinase 2 Mus musculus 14-19 19536776-2 2009 Lapatinib is a dual tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR) and HER-2. Lapatinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 104-109 19536776-5 2009 Lapatinib potently inhibited the growth of a HER-2 overexpressing gastric cancer cell line and demonstrated moderate activity in gastric and colon cancer cells with detectable HER-2 expression. Lapatinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 45-50 19536776-5 2009 Lapatinib potently inhibited the growth of a HER-2 overexpressing gastric cancer cell line and demonstrated moderate activity in gastric and colon cancer cells with detectable HER-2 expression. Lapatinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 176-181 19554571-1 2009 BACKGROUND: Lapatinib is a small molecule reversible tyrosine kinase inhibitor of EGFR and ErbB2 that shows in vitro and in vivo activity against a range of EGFR and ErbB2-dependent adult cancer cell lines and that has clinical efficacy against ErbB2-overexpressing breast cancer. Lapatinib 12-21 erb-b2 receptor tyrosine kinase 2 Mus musculus 91-96 19554571-1 2009 BACKGROUND: Lapatinib is a small molecule reversible tyrosine kinase inhibitor of EGFR and ErbB2 that shows in vitro and in vivo activity against a range of EGFR and ErbB2-dependent adult cancer cell lines and that has clinical efficacy against ErbB2-overexpressing breast cancer. Lapatinib 12-21 erb-b2 receptor tyrosine kinase 2 Mus musculus 166-171 19554571-1 2009 BACKGROUND: Lapatinib is a small molecule reversible tyrosine kinase inhibitor of EGFR and ErbB2 that shows in vitro and in vivo activity against a range of EGFR and ErbB2-dependent adult cancer cell lines and that has clinical efficacy against ErbB2-overexpressing breast cancer. Lapatinib 12-21 erb-b2 receptor tyrosine kinase 2 Mus musculus 166-171 19554571-10 2009 CONCLUSIONS: Lapatinib has little activity against the xenografts of the PPTP"s in vivo panel, and its in vitro activity occurs at concentrations above those associated with specific EGFR/ErbB2 inhibition. Lapatinib 13-22 erb-b2 receptor tyrosine kinase 2 Mus musculus 188-193 20459769-0 2010 Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model. Lapatinib 89-98 erb-b2 receptor tyrosine kinase 2 Mus musculus 57-62 20459769-3 2010 Recent studies demonstrate that lapatinib, a dual tyrosine kinase inhibitor of EGFR and HER-2 receptors, is clinically effective against HER-2-overexpressing metastatic breast cancer. Lapatinib 32-41 erb-b2 receptor tyrosine kinase 2 Mus musculus 88-93 20459769-3 2010 Recent studies demonstrate that lapatinib, a dual tyrosine kinase inhibitor of EGFR and HER-2 receptors, is clinically effective against HER-2-overexpressing metastatic breast cancer. Lapatinib 32-41 erb-b2 receptor tyrosine kinase 2 Mus musculus 137-142 20459769-11 2010 We also demonstrate that lapatinib altered EGFR/HER-2 signaling pathways reducing p-EGFR, p-HER-2, p-ERK1/2, p-AKT, c-Myc and PCNA levels. Lapatinib 25-34 erb-b2 receptor tyrosine kinase 2 Mus musculus 48-53 20459769-11 2010 We also demonstrate that lapatinib altered EGFR/HER-2 signaling pathways reducing p-EGFR, p-HER-2, p-ERK1/2, p-AKT, c-Myc and PCNA levels. Lapatinib 25-34 erb-b2 receptor tyrosine kinase 2 Mus musculus 92-97 19141783-1 2009 Lapatinib, a selective orally available inhibitor of epidermal growth factor receptor (EGFR) and ErbB2 receptor tyrosine kinases, is a promising agent for the treatment of breast cancer. Lapatinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 97-102 19047120-2 2008 The present studies were done to determine the effect of combining topotecan and the dual epidermal growth factor receptor/HER2 inhibitor lapatinib in tissue culture, a murine xenograft model, and a phase I clinical trial. Lapatinib 138-147 erb-b2 receptor tyrosine kinase 2 Mus musculus 123-127 18664652-7 2008 RESULTS: In vitro, lapatinib inhibited the phosphorylation of EGFR, HER2, and downstream signaling proteins; cell proliferation; and migration in 231-BR cells (both with and without HER2). Lapatinib 19-28 erb-b2 receptor tyrosine kinase 2 Mus musculus 68-72 18664652-7 2008 RESULTS: In vitro, lapatinib inhibited the phosphorylation of EGFR, HER2, and downstream signaling proteins; cell proliferation; and migration in 231-BR cells (both with and without HER2). Lapatinib 19-28 erb-b2 receptor tyrosine kinase 2 Mus musculus 182-186 18664652-10 2008 Immunohistochemical analysis revealed reduced phosphorylation of HER2 in 231-BR-HER2 cell-derived brain metastases from mice treated with the higher dose of lapatinib compared with 231-BR-HER2 cell-derived brain metastases from vehicle-treated mice (P < .001). Lapatinib 157-166 erb-b2 receptor tyrosine kinase 2 Mus musculus 65-69 18664652-10 2008 Immunohistochemical analysis revealed reduced phosphorylation of HER2 in 231-BR-HER2 cell-derived brain metastases from mice treated with the higher dose of lapatinib compared with 231-BR-HER2 cell-derived brain metastases from vehicle-treated mice (P < .001). Lapatinib 157-166 erb-b2 receptor tyrosine kinase 2 Mus musculus 80-84 18664652-10 2008 Immunohistochemical analysis revealed reduced phosphorylation of HER2 in 231-BR-HER2 cell-derived brain metastases from mice treated with the higher dose of lapatinib compared with 231-BR-HER2 cell-derived brain metastases from vehicle-treated mice (P < .001). Lapatinib 157-166 erb-b2 receptor tyrosine kinase 2 Mus musculus 80-84 18664652-11 2008 CONCLUSIONS: Lapatinib is the first HER2-directed drug to be validated in a preclinical model for activity against brain metastases of breast cancer. Lapatinib 13-22 erb-b2 receptor tyrosine kinase 2 Mus musculus 36-40 34101105-8 2021 Mouse HER2+ breast cancer models treated with lapatinib were imaged with a peptide-based HER3-specific PET imaging agent (68Ga)HER3P1 to assess for dynamic changes in tumoral HER3 expression and uptake confirmed by biodistribution. Lapatinib 46-55 erb-b2 receptor tyrosine kinase 2 Mus musculus 6-10 18334220-6 2008 All ErbB4 residues contacted by lapatinib are conserved in the EGF receptor and HER2/ErbB2, which lapatinib also targets. Lapatinib 32-41 erb-b2 receptor tyrosine kinase 2 Mus musculus 80-84 18334220-6 2008 All ErbB4 residues contacted by lapatinib are conserved in the EGF receptor and HER2/ErbB2, which lapatinib also targets. Lapatinib 32-41 erb-b2 receptor tyrosine kinase 2 Mus musculus 85-90 18334220-6 2008 All ErbB4 residues contacted by lapatinib are conserved in the EGF receptor and HER2/ErbB2, which lapatinib also targets. Lapatinib 98-107 erb-b2 receptor tyrosine kinase 2 Mus musculus 80-84 18334220-6 2008 All ErbB4 residues contacted by lapatinib are conserved in the EGF receptor and HER2/ErbB2, which lapatinib also targets. Lapatinib 98-107 erb-b2 receptor tyrosine kinase 2 Mus musculus 85-90 17203189-10 2007 A synergistic inhibitory effect was observed with the combination of inhibitors of EGFR-HER-2/neu (lapatinib or GW2974) and Bcl-2 (GX15-070 or HA14-1) on the growth of the MCF-7, MCF/18, and MTR-3 human breast cancer cell lines. Lapatinib 99-108 erb-b2 receptor tyrosine kinase 2 Mus musculus 94-97 18413839-8 2008 ErbB2 mutants associated with lapatinib resistance transformed NIH-3T3 cells, including L755S and T733I mutations known to occur in human breast and gastric carcinomas, supporting a direct mechanism for lapatinib resistance in ErbB2-driven human cancers. Lapatinib 30-39 erb-b2 receptor tyrosine kinase 2 Mus musculus 0-5 18413839-8 2008 ErbB2 mutants associated with lapatinib resistance transformed NIH-3T3 cells, including L755S and T733I mutations known to occur in human breast and gastric carcinomas, supporting a direct mechanism for lapatinib resistance in ErbB2-driven human cancers. Lapatinib 203-212 erb-b2 receptor tyrosine kinase 2 Mus musculus 0-5 32795383-3 2020 METHODS: To investigate a potential protective effect of adipocyte-conditioned medium on HER2 positive breast cancer cells exposed to tyrosine kinase inhibitors (TKI) such as lapatinib, we analyzed the sensitivity of HER2 positive breast cancer models in vitro and in vivo on SCID mice in the presence or absence of adipocytes or adipocyte-conditioned medium. Lapatinib 175-184 erb-b2 receptor tyrosine kinase 2 Mus musculus 89-93 34101105-9 2021 Subsequently, HER2+ cell lines were treated with the HER2 inhibitor lapatinib as well HER3-specific siRNA to assess for changes in viability and correlate with HER3 expression upregulation. Lapatinib 68-77 erb-b2 receptor tyrosine kinase 2 Mus musculus 53-57 34101105-12 2021 Evaluation of (68Ga)HER3P1 uptake in mice implanted with the HER2+ breast cancer cell lines MDA-MB453 or HCC-1569 prior to and after treatment with lapatinib demonstrated a significant increase in MDA-MB453 tumors only, consistent with in vitro findings. Lapatinib 148-157 erb-b2 receptor tyrosine kinase 2 Mus musculus 61-65 33176309-2 2020 Lapatinib simultaneously inhibits EGFR and HER2, leading to apoptosis. Lapatinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 43-47 35431974-6 2022 Our findings suggest that PTPRO is not only able to serve as an independent prognostic indicator, but upregulating PTPRO can also reverse the lapatinib resistance of ERBB2-positive breast cancer. Lapatinib 142-151 erb-b2 receptor tyrosine kinase 2 Mus musculus 166-171 32490320-12 2020 The functional relevance was tested by administering lapatinib, which is a dual tyrosine kinase inhibitor of erythroblastic oncogene B-2 (ErbB2) and EGFR signaling, to NEMODeltahepa/JNKDeltahepa mice. Lapatinib 53-62 erb-b2 receptor tyrosine kinase 2 Mus musculus 109-136 32490320-12 2020 The functional relevance was tested by administering lapatinib, which is a dual tyrosine kinase inhibitor of erythroblastic oncogene B-2 (ErbB2) and EGFR signaling, to NEMODeltahepa/JNKDeltahepa mice. Lapatinib 53-62 erb-b2 receptor tyrosine kinase 2 Mus musculus 138-143 30125265-0 2018 Lapatinib, a Dual Inhibitor of Epidermal Growth Factor Receptor (EGFR) and HER-2, Enhances Radiosensitivity in Mouse Bladder Tumor Line-2 (MBT-2) Cells In Vitro and In Vivo. Lapatinib 0-9 erb-b2 receptor tyrosine kinase 2 Mus musculus 75-80 30279968-4 2018 Furthermore, capns1 knockout in a tumor derived cell line correlated with enhanced sensitivity to the chemotherapeutic doxorubicin and the HER2/EGFR tyrosine kinase inhibitor lapatinib. Lapatinib 175-184 erb-b2 receptor tyrosine kinase 2 Mus musculus 139-143 31209328-5 2019 RESULTS: Lapatinib increased intratumoral HER2 protein, which encouraged resistance to this treatment in mouse models. Lapatinib 9-18 erb-b2 receptor tyrosine kinase 2 Mus musculus 42-46 30786890-7 2019 The synergistic effects of lovastatin with the ErbB2 inhibitor lapatinib were evaluated using an ErbB2-positive breast cancer xenograft mouse model. Lapatinib 63-72 erb-b2 receptor tyrosine kinase 2 Mus musculus 47-52 30786890-11 2019 Lovastatin also synergized with lapatinib to strongly suppress the in vivo growth of ErbB2-positive breast cancer xenografts. Lapatinib 32-41 erb-b2 receptor tyrosine kinase 2 Mus musculus 85-90 30125265-1 2018 BACKGROUND The aim of this study was to evaluate the effect of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) and HER-2, on the radiosensitivity of murine bladder tumor line-2 (MBT-2) cells in vitro and in vivo. Lapatinib 63-72 erb-b2 receptor tyrosine kinase 2 Mus musculus 138-143 30125265-6 2018 RESULTS Lapatinib pretreatment, combined with radiation, decreased MBT-2 cell survival, and suppressed radiation-activated levels of p-EGFR and p-HER-2. Lapatinib 8-17 erb-b2 receptor tyrosine kinase 2 Mus musculus 146-151 30125265-10 2018 CONCLUSIONS Lapatinib treatment enhanced the radiation sensitivity in an in vitro and in vivo murine bladder cancer model by decreasing radiation-mediated EGFR and HER-2 activation, and by causing DNA damage leading to cell apoptosis. Lapatinib 12-21 erb-b2 receptor tyrosine kinase 2 Mus musculus 164-169 28061785-0 2017 Short-term early exposure to lapatinib confers lifelong protection from mammary tumor development in MMTV-erbB-2 transgenic mice. Lapatinib 29-38 erb-b2 receptor tyrosine kinase 2 Mus musculus 106-112 29109274-5 2017 Two breast cancer drugs, docetaxel and HER2-targeted lapatinib, were delivered to MDA-MB-231 and SKBR3 (overexpressing HER2) breast cancer cells and compared with release in noncancerous RAW 264.7 macrophage cells. Lapatinib 53-62 erb-b2 receptor tyrosine kinase 2 Mus musculus 39-43 28061785-2 2017 Previous studies have demonstrated that administration of EGFR/erbB-2-targeting lapatinib to MMTV-erbB-2 transgenic mice inhibited mammary tumor development. Lapatinib 80-89 erb-b2 receptor tyrosine kinase 2 Mus musculus 63-69 28061785-2 2017 Previous studies have demonstrated that administration of EGFR/erbB-2-targeting lapatinib to MMTV-erbB-2 transgenic mice inhibited mammary tumor development. Lapatinib 80-89 erb-b2 receptor tyrosine kinase 2 Mus musculus 98-104 28061785-8 2017 Then, we tested the efficacy of brief exposure to lapatinib (100 mg/kg/day for 8 weeks), beginning at 16 weeks of age, in the prevention of mammary tumor development in MMTV-erbB-2 mice. Lapatinib 50-59 erb-b2 receptor tyrosine kinase 2 Mus musculus 174-180 28061785-12 2017 Molecular analysis indicated that lapatinib inhibited phosphorylation and expression of EGFR, erbB-3, erbB-2, Akt1, and Erk1/2 in premalignant mammary tissues. Lapatinib 34-43 erb-b2 receptor tyrosine kinase 2 Mus musculus 102-108 28061785-16 2017 Our findings support further clinical testing to explore the benefit of shorter lapatinib exposure in the prevention of erbB-2-mediated carcinogenesis. Lapatinib 80-89 erb-b2 receptor tyrosine kinase 2 Mus musculus 120-126 27197158-7 2016 In HER2-amplified cells, exposure to an mTORC1/2 dual kinase inhibitor decreased Akt-dependent cell survival, including in cells resistant to lapatinib, where cytotoxicity could be restored. Lapatinib 142-151 erb-b2 receptor tyrosine kinase 2 Mus musculus 3-7 26692570-5 2016 Consistently, receptor binding assays and western blotting demonstrate that beta2ARs levels are markedly increased in ErbB2(tg) myocardium and reduced by EGFR/ErbB2 inhibitor, lapatinib. Lapatinib 176-185 erb-b2 receptor tyrosine kinase 2 Mus musculus 159-164 27293993-7 2016 Furthermore, low-dose lapatinib treatment, starting at the early stages of mammary grand transformation in the MMTV-neu* mouse model, significantly delayed mammary tumor initiation and progression, extended tumor-free survival, which corresponded to effective inhibition of HER2/Akt signaling and downregulation of GLUT4 in vivo. Lapatinib 22-31 erb-b2 receptor tyrosine kinase 2 Mus musculus 274-278 26474677-1 2015 The combination of high dose of oral lapatinib (LAPA), a HER2 tyrosine kinase inhibitor, with intravenous paclitaxel (PTX) exhibited a clinical survival advantage compared with PTX alone against HER2 positive breast cancer. Lapatinib 37-46 erb-b2 receptor tyrosine kinase 2 Mus musculus 57-61 26474677-6 2015 The most synergistic effect was found between LAPA and PTX on the cell line overexpressing both HER2 and P-gp, and the mechanisms related to LAPA-induced inhibition on P-gp expression, more G2/M phase arrest of PTX and more uptake of PTX in tumor cells. Lapatinib 46-50 erb-b2 receptor tyrosine kinase 2 Mus musculus 96-100 26474677-6 2015 The most synergistic effect was found between LAPA and PTX on the cell line overexpressing both HER2 and P-gp, and the mechanisms related to LAPA-induced inhibition on P-gp expression, more G2/M phase arrest of PTX and more uptake of PTX in tumor cells. Lapatinib 141-145 erb-b2 receptor tyrosine kinase 2 Mus musculus 96-100 26474677-9 2015 To summarize, this localized co-delivery system with good synergistic effects between LAPA and PTX might offer a potential strategy for HER2 and P-gp positive breast cancer. Lapatinib 86-90 erb-b2 receptor tyrosine kinase 2 Mus musculus 136-140 26474677-1 2015 The combination of high dose of oral lapatinib (LAPA), a HER2 tyrosine kinase inhibitor, with intravenous paclitaxel (PTX) exhibited a clinical survival advantage compared with PTX alone against HER2 positive breast cancer. Lapatinib 37-46 erb-b2 receptor tyrosine kinase 2 Mus musculus 195-199 26474677-1 2015 The combination of high dose of oral lapatinib (LAPA), a HER2 tyrosine kinase inhibitor, with intravenous paclitaxel (PTX) exhibited a clinical survival advantage compared with PTX alone against HER2 positive breast cancer. Lapatinib 48-52 erb-b2 receptor tyrosine kinase 2 Mus musculus 195-199 26086099-10 2015 Furthermore, lapatinib, an inhibitor of both ErbB1 and ErbB2, effectively masked the effect of TSA on the inhibition of A549 cell proliferation and migration, suggesting TSA does work, at least in part, by downregulating ErbB receptors. Lapatinib 13-22 erb-b2 receptor tyrosine kinase 2 Mus musculus 55-60 26337386-0 2015 Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors. Lapatinib 93-102 erb-b2 receptor tyrosine kinase 2 Mus musculus 53-57 26337386-3 2015 Tumor progression is accompanied by changes in the biophysical properties of the tissue, and we asked whether matrix rigidity modulated the sensitive versus resistant states in HER2-amplified breast cancer cell responses to the HER2-targeted kinase inhibitor lapatinib. Lapatinib 259-268 erb-b2 receptor tyrosine kinase 2 Mus musculus 177-181 26337386-6 2015 Reduction of YAP in vivo in mice also slowed the growth of implanted HER2-amplified tumors, showing a trend of increasing sensitivity to lapatinib as YAP decreased. Lapatinib 137-146 erb-b2 receptor tyrosine kinase 2 Mus musculus 69-73 25249538-8 2014 Accordingly, lapatinib, an EGFR/HER2 tyrosine kinase inhibitor, as well as metformin, reduced the tumor growth of cells overexpressing NTS and NTSR1. Lapatinib 13-22 erb-b2 receptor tyrosine kinase 2 Mus musculus 32-36 25700543-3 2015 Previous studies have indicated that lapatinib, a selective small-molecular dual-tyrosine kinase inhibitor of HER2 and EGFR, is effective in reducing cancer progression and metastasis, indicating that it might be a candidate for TNBC treatment. Lapatinib 37-46 erb-b2 receptor tyrosine kinase 2 Mus musculus 110-114 25375038-4 2015 Inhibiting EGFR or HER2 signaling with oral lapatinib (100 mg/kg), a dual tyrosine kinase inhibitor for both EGFR and HER2, suppressed circulating PRL by 72% and attenuated tumor PRL expression by 80% and also attenuated downstream tumor EGFR/HER2 signaling. Lapatinib 44-53 erb-b2 receptor tyrosine kinase 2 Mus musculus 19-23 25375038-4 2015 Inhibiting EGFR or HER2 signaling with oral lapatinib (100 mg/kg), a dual tyrosine kinase inhibitor for both EGFR and HER2, suppressed circulating PRL by 72% and attenuated tumor PRL expression by 80% and also attenuated downstream tumor EGFR/HER2 signaling. Lapatinib 44-53 erb-b2 receptor tyrosine kinase 2 Mus musculus 118-122 25375038-4 2015 Inhibiting EGFR or HER2 signaling with oral lapatinib (100 mg/kg), a dual tyrosine kinase inhibitor for both EGFR and HER2, suppressed circulating PRL by 72% and attenuated tumor PRL expression by 80% and also attenuated downstream tumor EGFR/HER2 signaling. Lapatinib 44-53 erb-b2 receptor tyrosine kinase 2 Mus musculus 118-122 25347743-6 2015 Taken together, these data suggest that targeting Fer alone, or in combination with LPN, may be of therapeutic benefit in HER2(+) breast cancer. Lapatinib 84-87 erb-b2 receptor tyrosine kinase 2 Mus musculus 122-126 26261492-6 2015 Additional studies revealed that overexpression of erbB2 downregulated three erbB3-targeting miRNAs, miR-125a, miR-125b, and miR-205, whereas the erbB2 kinase inhibitor (lapatinib) significantly enhanced expression of the three miRNAs in breast cancer cells, suggesting that erbB2 might regulate erbB3 expression through a miRNA-dependent mechanism. Lapatinib 170-179 erb-b2 receptor tyrosine kinase 2 Mus musculus 51-56 26261492-6 2015 Additional studies revealed that overexpression of erbB2 downregulated three erbB3-targeting miRNAs, miR-125a, miR-125b, and miR-205, whereas the erbB2 kinase inhibitor (lapatinib) significantly enhanced expression of the three miRNAs in breast cancer cells, suggesting that erbB2 might regulate erbB3 expression through a miRNA-dependent mechanism. Lapatinib 170-179 erb-b2 receptor tyrosine kinase 2 Mus musculus 146-151 26261492-6 2015 Additional studies revealed that overexpression of erbB2 downregulated three erbB3-targeting miRNAs, miR-125a, miR-125b, and miR-205, whereas the erbB2 kinase inhibitor (lapatinib) significantly enhanced expression of the three miRNAs in breast cancer cells, suggesting that erbB2 might regulate erbB3 expression through a miRNA-dependent mechanism. Lapatinib 170-179 erb-b2 receptor tyrosine kinase 2 Mus musculus 146-151 25114718-1 2014 BACKGROUND: HER2 antagonists (anti-HER2; e.g., trastuzumab and lapatinib) are effective in treating an aggressive form of breast cancer (BC), but can cause cardiotoxicity due to the disruption in neuregulin (NRG)/HER2+ ligand receptor signalling. Lapatinib 63-72 erb-b2 receptor tyrosine kinase 2 Mus musculus 12-16 25114718-1 2014 BACKGROUND: HER2 antagonists (anti-HER2; e.g., trastuzumab and lapatinib) are effective in treating an aggressive form of breast cancer (BC), but can cause cardiotoxicity due to the disruption in neuregulin (NRG)/HER2+ ligand receptor signalling. Lapatinib 63-72 erb-b2 receptor tyrosine kinase 2 Mus musculus 35-39 25114718-1 2014 BACKGROUND: HER2 antagonists (anti-HER2; e.g., trastuzumab and lapatinib) are effective in treating an aggressive form of breast cancer (BC), but can cause cardiotoxicity due to the disruption in neuregulin (NRG)/HER2+ ligand receptor signalling. Lapatinib 63-72 erb-b2 receptor tyrosine kinase 2 Mus musculus 35-39 24675532-9 2014 Mechanistically, we identified ErbB2 protein stabilization and activation as a novel mechanism of BEZ235 resistance, which was reversed by subsequent treatment with lapatinib + BEZ235 combination. Lapatinib 165-174 erb-b2 receptor tyrosine kinase 2 Mus musculus 31-36